(Q38184622)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490883%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

title

Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490883%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490883%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

Vittore Cereda

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490883%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Vincenzo Formica

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490883%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Gioia Massimiani

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490883%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Livia Tosetto

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490883%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

language of work or name

English

0 references

publication date

3 February 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490883%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

7 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490883%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490883%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490883%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

469-487

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490883%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Castration-recurrent prostate cancer is not androgen-independent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

CYP17 inhibition as a hormonal strategy for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Alpha emitter radium-223 and survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Increased survival with enzalutamide in prostate cancer after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Steroidogenesis in the adrenal dysfunction of critical illness: impact of etomidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Androgen receptor signaling in androgen-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Molecular determinants of resistance to antiandrogen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Microarray analysis of prostate cancer progression to reduced androgen dependence: studies in unique models contrasts early and late molecular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Androgen receptor mutations in high-grade prostate cancer before hormonal therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Molecular biology of the androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Androgen receptor and its splice variants in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Development of prostate cancer treatment: the good news

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Recurrent gene fusions in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Integrative genomic profiling of human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1; Pten mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

TOR signaling in growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

High expression of the Met receptor in prostate cancer metastasis to bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

A sex-specific role for androgens in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

The cross-talk between dendritic and regulatory T cells: good or evil?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

ARN-509: a novel antiandrogen for prostate cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Small heat shock proteins in cancer therapy and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Role of fibroblast growth factor receptor signaling in prostate cancer cell survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Angiogenesis and anti-angiogenic therapy in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

Augmentation of T Cell Levels and Responses Induced by Androgen Deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.885950

10.1517/13543784.2014.885950

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490883%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference